AU2013205089B2 — Novel compounds as opioid receptor modulators
Assigned to Janssen Pharmaceutica NV · Expires 2013-12-19 · 12y expired
What this patent protects
Abstract The present invention is directed to novel opioid receptor modulators of Formula: (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated …
USPTO Abstract
Abstract The present invention is directed to novel opioid receptor modulators of Formula: (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors. Figure 1 Figure 1 Recording distensions @ 4 min intervals 2 minutes 20 2f distension pressures- 40 4D 60 80 40 60 90 40 60 80 (mmH) intrcoonic EMGrecordings b"lcnposttned (distension time- 20 se) Zymosan treatment 0 hours 4 5 6 t t t t 1.3 nl ymsan A record treat wit record (25 m/d in 30% EtOH) oiound inieCiclnis Cnilminisinto ea
Drugs covered by this patent
- Viberzi (ELUXADOLINE) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.